Under the agreement, Dowpharma will use its pfenex expression technology to speed the development process of the vaccine. Oral administration of BT-VACC produces protective antibodies that afford protection
The NDA amendment includes new clinical data that address the efficacy, dosing, duration of wear, and tolerability of MTS. The FDA has confirmed that the amendment will receive
The phase III clinical trials for retigabine will consist of two global studies, the first in the United States, Mexico and South America with up to 45 sites,
The company were keen to find out whether patients displayed any adverse reaction to tgAAC94 being injected locally into the joints, and are encouraged to have found that
The initiation of the early stage trial triggers a $2 million milestone payment to Arena under its cardiovascular disease collaboration with Merck to develop compounds targeted at a
Enrollment of patients into the trial, which will seek to establish the toxicities and maximum tolerated dose of Cloretazine in patients, and observe the efficacy of the drug,
The deal should give Invitrogen an opportunity to enter new markets in immunology, oncology and neurodegenerative disease, will strengthen its proteomics portfolio, and reinforce its research arm. Invitrogen
Santarus, a pharmaceutical company focused on therapies for gastrointestinal diseases and disorders, expects the FDA will complete its review or give some response by March 26, 2006. If
Researchers at the University of Rochester Medical Center have discovered a single biochemical feature of disease-causing molecules (pathogens) that, if changed, would force them to provoke an attack
Dr Mike Youle from the Royal Free Hospital, London said: “We are seeing a consistent Fuzeon effect with these new drugs and I believe these data must change
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.